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Abstract 
BACKGROUND: Treatment of severe alopecia areata remains very difficult, especially in alopecia areata totalis 
and alopecia areata universalis. Methotrexate is known to be effective in the treatment of severe and chronic 
autoimmune disorders.  
OBJECTIVE: To assess the effectiveness and safety of MTX in combination with mini pulse dose of 
methylprednisolone in the treatment of severe alopecia areata. 
PATIENTS AND METHODS: The open, uncontrolled study compared pre-treatment and after-treatment. Thirty-
eight patients (age 16-64) with severity AA (SALT score > 50 %) visiting National hospital of Dermatology and 
Venereology from April-2004 to September-2015 were enrolled. All patients received oral methylprednisolone 
24mg/day for 3 consecutive days of a week in combination with oral MTX 7,5 mg weekly. This regimen is 
maintained up to 12 weeks and follow-up until to 6 months. 
RESULTS: After 6 months, 60.5% of patients show complete hair growth (good response) and 18.4% shows the 
medium response. There is a significant SALT score reduction: mean baseline SALT score 84.39 ± 17.03 
compared to mean post-treatment SALT score 24.19 ± 29.42. Good clinical improvement noted in after 3 months. 
We do not observe any side- effects related to oral MTX and oral methylprednisolone, and no patients had to 
withdrawal treatment due to side- effects. 
CONCLUSION: Combination Methotrexate and mini pulse dose of methylprednisolone are effective and safe in 
treatment severity alopecia areata. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Alopecia areata (AA) is one of the most 
common diseases of hair loss, the pathogenesis of 
the disease is still unknown but recently, it is 
considered an autoimmune disease [1], [2], [3], [4]. It 
is characterised by recurrent non-cicatricial hair loss 
that can affect any hair-bearing area such as the 
scalp, beard, eyelashes, and eyebrows. Patients 
usually start silently, develop persistently and relapse 
[5]. Although it is a benign condition and most patients 
are asymptomatic, but it can cause emotional and 
psychosocial distress. Incidence varies according to 
race and geography. In the United States, an 
estimated 4.5 million people are infected. It accounts 
for 0.1 to 0.2% of the world population [6], [7]. The 
disease can occur at any ages and in both sexes, but 
predominantly in young people aged 15-45, rarely 
seen in older adults and young children. Male and 
females are affected equally, and the prevalence is 
almost the same for all ethnic groups [8], [9]. Some 
factors related to this disease included family, allergic, 
immunological, endocrine, psychological trauma or 
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infection. 
Treatment of severe alopecia areata remains 
very difficult, especially in alopecia areata totalis and 
alopecia areata universalis [10], [11], [12], [13]. 
Corticosteroids are the most commonly used agents 
in the treatment of AA, especially in the extensive 
forms, but the success of these agents is controversial 
[4], [12], [14]. In several studies, they are reported that 
alone corticosteroid treatment is not effective and the 
relapse rate is still very high [12], [13], [15]. 
Methotrexate is known to be effective in the treatment 
of severe and chronic autoimmune disorders, and it is 
a safe and effective corticosteroid-sparing agent [16]. 
Recently, MTX combination with oral corticosteroid 
has been reported effect and safe in severe AA [17], 
[18], [19], [20]. So we want to assess the 
effectiveness and safety of MTX in combination with 
mini pulse dose of methylprednisolone in the 
treatment severe alopecia areata. 
 
 
Materials and Methods 
 
Study design and design: Thirty-eight patients 
(age 16 -64) with severity AA (SLAT > 50 %) visiting 
NHDV from April-2004 to September-2015 were 
enrolled. The diagnosis of alopecia areata was based 
on clinical criteria. Severity alopecia areata patients 
were identified when SALT scores from 50% to 95% 
of the scalp area. Alopecia areata totalis (AT) is when 
hair loss from 95 to 100% of scalp area without hair 
loss in the body. Alopecia areata universalis (AU) 
means hair loss all of the scalp and in the body. 
Treatment regimen: The regimen included 
oral methylprednisolone 24 mg/day for 3 consecutive 
days of a week in combination with oral MTX 7,5mg/ 
week. This regimen is maintained up to 12 weeks and 
follow-up until to 6 months. 
Follow-up and outcome assessment: The 
degree of hair loss was assessed by SALT (Severity 
of Alopecia Tool) score in before treatment and 
monthly (every 4 weeks) after treatment. 
Transaminase levels (AST, ALT) and complete blood 
count were performed before treatment and after 3 
months of treatment (12 weeks). Photographs of hair 
loss area were taken for each visit and recorded in 
files. Evaluation of the efficacy treatment used SALT 
score and patient satisfaction. 
- Good response: Hair grows well, thick, 
black, covering the area of scalp and body, patients 
are satisfied. 
- Moderate response: hair grows thin, brown 
or white, partially covered, patients are satisfied. 
- Poor response: hair does not grow, patients 
are not satisfied. 
Follow the side effects: acne, hypertension, 
stomach pain, headache, nausea, elevation of 
transaminase levels, count blood cell. 
Exclusion criteria included the patient who 
has SALT score < 50%, patients are contraindicated 
for MTX, steroids and the patient who has pregnant 
women or intended pregnancy and breastfeeding. 
 
Statistical analysis 
The data were analysed by SPSS20.0 version. 
Results were reported as the mean ± standard 
deviation (SD) for the quantitative variables and 
percentages for the categorical variables. Analyses for 
normal distribution fitness were performed. Student t-
test was used for intergroup comparison. Chi-square 
test was applied for the analysis of categorical 
variables. P values < 0.05 were considered to be 
statistically significant. 
 
 
Results 
 
A total of 38 patients had severe alopecia 
areata, including 31 (82%) female and 7 (18%) males 
were enrolled in this study. The mean age of the 
patients was 29.61 ± 12.07 and the 
meandiseasedurationwas 26.47 ± 30.1 months. 
Eighteen patients (47.4%) had severe AA, and 9 
patients (23.7%) had AT and11 patients (28.9%) had 
AU. 
 
Figure 1: The effectiveness of treatment: patient at baseline (A); 
after one month of treatment (B); after 6 months of treatment (C) 
 
Follow-up after 1 month of treatment showed 
that only 3 patients (7.9%) had a good response, 18 
patients (47.4%) had a medium response, and 17 
(44.7%) patients had a poor response.  
 
Figure 2:  The effectiveness of treatment: patient at baseline   (A); 
after one month of treatment (B); after 6 months of treatment (C) 
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However, at the end of 3 months of treatment, 
22 patients (57.9%) had hair re-growth completely, 9 
patients (23.7%) had hair re-growth partially, and 7 
patients (18.4%) had still a poor response.  
After 6 months of follow-up in this study, we 
found 23 patients (60.5%) had a good response and 9 
patients (23.7%) had a medium response, and in 
those patients had no new patch or recurrent after 
stopping treatment as presented in Table 1.  
Table 1: The efficacy of treatment every month 
Responses 
1-month 
treatment 
2-months 
treatment 
3-months 
treatment 
6-months 
treatment 
Good response 
7.9 
(3/38) 
47.4 
(18/38) 
57.9 
(22/38) 
60.5 
(23/38) 
Medium response 
47.4 
(18/38) 
28.9 
(11/38) 
23.7 
(9/38) 
23.7 
(9/38) 
Poor Response 
44.7 
(17/38) 
23.7 
(9/38) 
18.4 
(7/38) 
15.8 
(6/38) 
Total 38 38 38 38 
 
The area of hair loss decreases in each 
visited, SALT score in before treatment was 84.39 ± 
17.03%, after 1-month treatment reduced to 65.10 ± 
26.29%, and decreased dramatically after 2-months 
treatment was 45.67 ± 28.21% after 3-months 
treatment was 29.97 ± 29.67%. At the end of the 
study, the area of hair loss according to SALT was 
24.19 ± 29.42% as shown in Table 2. No patients in 
our study had side effected related to oral 
corticosteroid and MTX. 
Table 2: The SALT score in every month follow-up 
SALT Score Mean ± SD P (before- after) 
Before treatment 84.39 ± 17.03 p < 0.05 
After 1 month 65.10 ± 26.29 
After 2 months 45.67 ± 28.21 
After 3 months 29.97 ± 29.67 
After 6 months 24.19 ± 29.42 
 
 
 
Discussion 
 
This study shows that there is a significant 
clinical improvement when using a combination of 
methotrexate and mini pulse dose of 
methylprednisolone in treating alopecia areata, 
especially in the severe cases. 
Over the past several years, the treatment of 
alopecia areata is very difficult; no therapy has long-
term effects, the rate of recurrence is still high. 
Systemic corticosteroid was used in the treatment of 
hair loss in many years [21], [22]. This drug is 
effective, but the use of long-term drug causes many 
side effects [10], [14], [23], [24]. Joly (2006) was 
treated 22 patients had severe AA by using MTX and 
corticosteroid. These patients were treated with MTX 
alone (6 patients) or in combination with low dose oral 
prednisolone (16 patients). The dose of MTX varies 
from 15-25 mg/week; the dose of prednisolone varies 
from 10-20 mg/day. Results showed that the number 
of patients with hair grows completely were 14/22 
patients (64%). No side effects have been reported. A 
reported by Chateaux and colleagues (2010) found 
that using corticosteroids in combination with MTX 
resulted in hair growth in 63% of patients. The dosage 
of MTX is 15-25 mg/week; the average duration of 
treatment is 3 months [18]. Royer et al., study (2011), 
14 children (eight girls and six boys) aged between 8 
and 18 years (mean 14.7) treated with MTX. The 
mean maximal dose was 18.9 mg weekly (range 15-
25 mg/week), and the mean duration of treatment was 
14.2 months (range 1 to 31 months). MTX was 
considered as successful (regrowth > 50% of hair) for 
five of them [19]. Comparison with other authors' 
studies also suggests that response rates for 
combination therapy are very high [20]. These studies 
have shown MTX to be effective in treated severe AA, 
with good response rates from 57 to 64% [24]. Thus 
our study used this regimen for a better outcome. It 
also helps to reduce the side effects of daily 
corticosteroids and to prevent recurrence of hair loss 
after stopping the drug. The results of recent studies 
suggest that alopecia areata are more related to 
immune dysfunction due to the presence of TCD4 and 
TCD8-active lymphocytes around the progressive hair 
follicles. Therefore, treatment of hair loss by using 
immunosuppressive drugs has been shown to be 
effective [23], [25], [26], [27], [28].  
In conclusion, our study showed that no 
patient had severe side-effected had to stop 
treatment, only 2/38 (0.05%) patients had a 
headache, 3/38 (0.07%) patients had to feel vomiting. 
The results of this study were suitable for different 
research. After 3 months, we stopped these drug and 
follow-up the patients in 3 months next, but in the 
patients who responded, no patients had recurred. 
Compared with other single steroid studies, the 
relapse rate was relatively high, maybe over 50% of 
cases [10], [14]. The recurrence rate in our study was 
much lower than that reported by Joly [17]. Thus, we 
think this may be a good approach that can be applied 
clinically as it is effective, especially in patients who 
do not respond to other methods. 
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